A novel hybrid series of nonpeptide CCK-B receptor antagonists has bee
n designed from two known series derived from asperlicin. An efficient
synthesis of 2-aminoquinazolinone, an intermediate for the synthesis
of a targeted analog, has been developed. (C) 1997 Elsevier Science Lt
d.